Fig. 2: Clinical course of high-grade meningioma patients treated with pembrolizumab.
From: Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Time of best radiographic response (as defined by TIMC), death, and study-limiting toxicity for the patient population. The arrow at the end of the bar indicates the time at which the patient was last known to be alive at the time of data analysis. The dashed line at 6 months is the threshold of the primary endpoint (PFS-6). Patients marked in blue had extracranial or metastatic meningiomas. One patient (MEN_06) was excluded from this schematic, as they withdrew consent one week after enrollment before receiving pembrolizumab.
